GB Patent

GB9314893D0 — Quinazoline derivatives

Assigned to Syngenta Ltd · Expires 1993-09-01 · 33y expired

What this patent protects

The invention concerns quinazoline derivatives of the formula I <CHEM> wherein R<1> includes hydroxy, amino, hydroxyamino, (1-4C)alkoxy, (1-4C)alkylamino and di-[(1-4C)alkyl]amino; R<3> is halogeno; n is 1, 2 or 3 and R<2> includes hydrogen, hydroxy, halo…

USPTO Abstract

The invention concerns quinazoline derivatives of the formula I <CHEM> wherein R<1> includes hydroxy, amino, hydroxyamino, (1-4C)alkoxy, (1-4C)alkylamino and di-[(1-4C)alkyl]amino; R<3> is halogeno; n is 1, 2 or 3 and R<2> includes hydrogen, hydroxy, halogeno and (1-4C)alkyl; or a pharmaceutically-acceptable salt thereof; processes for their preparation; pharmaceutical compositions containing them; and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of cancer.

Drugs covered by this patent

Patent Metadata

Patent number
GB9314893D0
Jurisdiction
GB
Classification
—
Expires
1993-09-01
Drug substance claim
No
Drug product claim
No
Assignee
Syngenta Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.